Researchers track Long-Term safety of rare blood disorder treatment
NCT ID NCT07413250
Summary
This study aims to understand the long-term safety of adding the drug danicopan to standard treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. Researchers will analyze existing health data from about 50 adult patients already taking these medications. The goal is to monitor for side effects and complications over time to ensure the treatment remains safe for ongoing use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.